Skip to main content

Surrozen, Inc 10-Q for FY2026 Q3

Surrozen, Inc. (SRZN)

10-Q 2026-11-09 For: 2026-09-30
View Original
Added on November 09, 2026

About this 10-Q

Surrozen, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Surrozen received FDA clearance for SZN-8141 in October 2026 and dosed its first patient in the DUET Phase 1b/2a study. It reported a $207.1 million nine-month net loss, $100.4 million cash, and a cash runway into 2029. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$0
compared with $983K a year earlier
Net loss
$129.72M
compared with a net loss of $71.64M a year earlier
Diluted EPS
-$11.02
compared with -$8.36 a year earlier